EUVIMEDOdkrijte EUVIMED
Übersichtsarbeit

Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

Joshua Burshtein, Milaan Shah, Danny Zakria, April W Armstrong, Alexandra K Golant, Alice B Gottlieb, Jeffrey M Weinberg, Leon Kircik, George Han, Richard G Langley, Andrea L Neimann, Mark Lebwohl

Journal of Drugs in Dermatology · 2024

DOI: 10.36849/jdd.8246 ↗

At a glance

Übersichtsarbeit in Journal of Drugs in Dermatology, 2024. Written by Joshua Burshtein and 11 co-authors. Major MEDLINE topics: Psoriasis, Consensus, Antibodies, Monoclonal, Humanized, Interleukin-17. Cited 2 times so far (Crossref).

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

BACKGROUND: Plaque psoriasis is a chronic, relapsing systemic illness that has a significant effect on quality of life. Bimekizumab is the first monoclonal antibody to target both interleukin (IL)-17A and IL-17F, and recently received Food and Drug Administration (FDA) approval for moderate to severe plaque psoriasis. Guidance is necessary regarding the safety of bimekizumab. METHODS: A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the safety of bimekizumab for moderate to severe psoriasis. A panel of 9 dermatologists and 1 rheumatologist with significant expertise in the treatment of psoriasis gathered to review the articles and create consensus statements on this new medication. A modified Delphi process was used to approve each statement, and strength of recommendation was assigned using the Strength of Recommendation Taxonomy criteria. RESULTS: The literature search produced 110 articles that met the criteria. A thorough screening of the studies for relevance to the research question resulted in 15 articles. These were distributed to all panelists for review prior to a roundtable discussion. The panel unanimously voted to adopt 5 consensus statements and recommendations, all of which were given a strength of "A". CONCLUSION: Bimekizumab has a safety profile consistent with other biologics, except for a higher risk of oral candidiasis. Its hepatic safety profile is comparable with other currently FDA-approved biologics for plaque psoriasis. In addition, the data do not support an association of bimekizumab with suicide, and the incidence of inflammatory bowel disease is not greater than the incidence of other IL-17 blockers. J Drugs Dermatol. 2024;23(8):592-599. doi:10.36849/JDD.8246.

Subjects

MeSH terms (MEDLINE)

PsoriasisConsensusAntibodies, Monoclonal, HumanizedInterleukin-17HumansDermatologic AgentsDelphi TechniqueSeverity of Illness Index

Substances

bimekizumabAntibodies, Monoclonal, HumanizedInterleukin-17Dermatologic AgentsIL17A protein, human

Cite

APA

Burshtein, J., Shah, M., Zakria, D., Armstrong, A. W., Golant, A. K., Gottlieb, A. B., Weinberg, J. M., Kircik, L., Han, G., Langley, R. G., Neimann, A. L., & Lebwohl, M. (2024). Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8246

Vancouver

Burshtein J, Shah M, Zakria D, Armstrong AW, Golant AK, Gottlieb AB, et al. Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.8246

BibTeX
@article{Burshtein2024,
  author = {Burshtein, Joshua and Shah, Milaan and Zakria, Danny and Armstrong, April W and Golant, Alexandra K and Gottlieb, Alice B and Weinberg, Jeffrey M and Kircik, Leon and Han, George and Langley, Richard G and Neimann, Andrea L and Lebwohl, Mark},
  title = {Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel},
  journal = {Journal of Drugs in Dermatology},
  year = {2024},
  doi = {10.36849/jdd.8246}
}
Start for free →